---
document_datetime: 2024-08-14 14:07:54
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lymphoseek-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lymphoseek-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.3686144
conversion_datetime: 2025-12-14 13:50:38.674609
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Lymphoseek

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0023/G            | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the | 18/04/2024                                  |                                             | SmPC, Annex II, Labelling and PL |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | applied during the manufacture of the finished product - Other variation                                                                                                                         |                    |            |                                  |                                                                                                                                                                                                                                                                          |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10313 /202305 | Periodic Safety Update EU Single assessment - tilmanocept                                                                                                                                        | 11/01/2024         | n/a        |                                  | PRAC Recommendation - maintenance authorised                                                                                                                                                                                                                             |
| PSUSA/10313 /202005 | Periodic Safety Update EU Single assessment - tilmanocept                                                                                                                                        | 14/01/2021         | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                        |
| T/0021              | Transfer of Marketing Authorisation                                                                                                                                                              | 06/08/2020         | 24/09/2020 | SmPC, Labelling and PL longer    |                                                                                                                                                                                                                                                                          |
| II/0019             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                | 30/04/2020         | 24/09/2020 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                          |
| PSUSA/10313 /201905 | Periodic Safety Update EU Single assessment - tilmanocept                                                                                                                                        | 28/11/2019 product | n/a no     |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                        |
| R/0016              | Renewal of the marketing authorisation.                                                                                                                                                          | 25/07/2019         | 16/09/2019 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lymphoseek in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0017             | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS Medicinal | 25/07/2019         | n/a        |                                  |                                                                                                                                                                                                                                                                          |
| PSUSA/10313         | Periodic Safety Update EU Single assessment -                                                                                                                                                    | 29/11/2018         | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| /201805             | tilmanocept                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                                  |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IAIN/0015/G         | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                 | 23/11/2018 | 16/09/2019 | SmPC, Annex II, Labelling and PL | authorised                        |
| IA/0014/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test product | 30/10/2018 | n/a no     | longer                           |                                   |
| PSUSA/10313 /201711 | procedure Periodic Safety Update EU Single assessment - tilmanocept Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/06/2018 | n/a        |                                  | PRAC Recommendation - maintenance |
| PSUSA/10313         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 30/11/2017 | n/a        |                                  | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| /201705             | tilmanocept                                                                                                                                                                                                                                                                                                                                                                                  |            |               |                               |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------------------------|-----------------------------------|
| IAIN/0011/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 16/11/2017 | 08/08/2018    | Annex II and PL               | authorised                        |
| IB/0010             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                          | 16/09/2017 | 08/08/2018 no | SmPC, Labelling and PL longer |                                   |
| PSUSA/10313 /201611 | Periodic Safety Update EU Single assessment - tilmanocept                                                                                                                                                                                                                                                                                                                                    | 09/06/2017 | n/a           |                               | PRAC Recommendation - maintenance |
| T/0007              | Application for Transfer of Marketing Authorisation from Navidea Biopharmaceuticals Limited to Norgine B.V. Transfer of Marketing Authorisation Medicinal product                                                                                                                                                                                                                            | 09/01/2017 | 23/01/2017    | SmPC, Labelling and PL        |                                   |
| PSUSA/10313 /201605 | Periodic Safety Update EU Single assessment - tilmanocept                                                                                                                                                                                                                                                                                                                                    | 01/12/2016 | n/a           |                               | PRAC Recommendation - maintenance |
| IA/0006/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                           | 25/11/2016 | n/a           |                               |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.c.1.a - Change in immediate packaging of the AS no   | longer authorised                |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| II/0004/G | - Qualitative and/or quantitative composition This was an application for a group of variations. B.II.a.2.c - Change in the shape or dimensions of the pharmaceutical form - Addition of a new kit for a radiopharmaceutical preparation with another fill volume B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for 15/09/2016 23/01/2017 Medicinal product                                                                                                                                                                                           | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where   | no longer   | authorised                        |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----------------------------------|
| PSUSA/10313 /201511 | Periodic Safety Update EU Single assessment - tilmanocept 09/06/2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | n/a         | PRAC Recommendation - maintenance |
| PSUSA/10313 /201505 | batch control/testing takes place Periodic Safety Update EU Single assessment - tilmanocept 03/12/2015 product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | n/a         | PRAC Recommendation - maintenance |
| IB/0002             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) 18/11/2015 Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | n/a         |                                   |